Get started
IRLAB THERAPEUTICS AB SER. AIRLAB THERAPEUTICS AB SER. AIRLAB THERAPEUTICS AB SER. A

IRLAB THERAPEUTICS AB SER. A

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

IRLAB_A fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The fim develops drugs for Parkinson's disease. It also offers IRL752 that targets dementia in Parkinson's disease. The company was founded in 2013 and is headquartered in Gothenburg, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

IRLAB_A does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company